NanOlogy LLC announced that initial safety and clinical outcomes from a Phase 2 clinical trial of intratumoral large surface area microparticle paclitaxel in locally advanced pancreatic cancer were published online ahead of print in Pancreas and two posters were presented at the ninth AACR Special Conference on Pancreatic Cancer in Boston reporting downstaging and immune data from the trial.
